TopoTarget A/S and Spectrum Pharmaceuticals Inc. has announced agreement to co-develop and commercialise belinostat,TopoTarget’s lead anticancer drug for cancer in North America and India. Belinostat, an HDAC inhibitor, is in registrational clinical trial in Peripheral T-Cell Lymphoma (PTCL) as monotherapy and in a randomized phase 2 clinical trial for cancer of unknown primary site (CUP) in combination with carboplatinum and paclitaxel (BelCaP). Belinostat is currently being investigated in 20 clinical trials in haematological and solid cancers in monotherapy as well as in combination therapies. Under the terms of the agreement, TopoTarget will receive an upfront payment of USD 30 million in cash. The total potential value of up-front and milestones (for both development and sales) of the agreement, in the event of full commercial success could exceed USD 350.